Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
NCT02276963
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG:
Ublituximab
Sponsor
Johns Hopkins University